Apatinib and trastuzumab-based chemotherapy for heavily treated primary trastuzumab-resistant metastatic breast cancer
ATBC had favorable effects for PTR breast cancer patients in later line treatment. The toxicity of the triple-combination regimen was tolerable; thus, further research should focus on identifying PTR patients who could benefit from ATBC.
Authors
- Xiaofeng Xie (ORCID: https://orcid.org/0000-0002-1661-343X)
- Xiaofeng Lan
- Lin Song (ORCID: https://orcid.org/0009-0002-2788-1074)
- Jiayi Huang (ORCID: https://orcid.org/0000-0003-0479-3645)
- Liping Chen (ORCID: https://orcid.org/0000-0003-1865-0231)
- Caiwen Du (ORCID: https://orcid.org/0000-0002-4709-2446)
- Xuelian Chen (ORCID: https://orcid.org/0000-0001-7488-6340)
- Xue Bai (ORCID: https://orcid.org/0000-0003-0170-9305)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Journal of Cancer Research and Therapeutics
- Published
- 2024-12-01
- DOI
- https://doi.org/10.4103/jcrt.jcrt_979_24
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.57